Table 2.
Metformin group | Reference group | Odds ratio (OR) and 95% confidence interval (95 CI) | ||||||
---|---|---|---|---|---|---|---|---|
Overall | Indication diabetes | Indication other | Overall | ORcrude (95 CI) | ORadj c (95 CI) | ORcrude (95 CI) | ORcrude (95 CI) | |
Birth defects | n = 392a, n (%) | n = 219, n (%) | n = 173, n (%) | n = 431b, n (%) | Metformin overall vs. reference | Metformin with diabetes vs. reference | Metformin without diabetes vs. reference | |
All birth defects without chromosomal or genetic origin | 32 (8.1) | 24 (11.0) | 8 (4.6) | 18 (4.2) | 2.04 (1.14–3.77) | 1.86 (0.95–3.71) | 2.84 (1.50–5.39) | 1.11 (0.45–2.53) |
Major birth defects | 20 (5.1) | 17 (7.8) | 3 (1.7) | 9 (2.1) | 2.52 (1.17–5.89) | 1.70 (0.70–4.38) | 3.95 (1.77–9.41) | 0.83 (0.18–2.81) |
Minor birth defects | 12 (3.1) | 7 (3.2) | 5 (2.9) | 9 (2.1) | 1.48 (0.62–3.66) | 1.92 (0.72–5.21) | 1.55 (0.55–4.21) | 1.40 (0.42–4.10) |
Cardiac birth defects | 9d (2.3) | 6 (2.7) | 3 (1.7) | 5e (1.2) | 2.00 (0.67–6.03) | 1.53 (0.43–5.72) | 2.40 (0.72–8.41) | 1.50 (0.31–6.20) |
Restricted to pregnancies with information on the presence or absence of a birth defect: 28 birth defects (16 major and 12 minor) identified among 378 live born infants and 4 defects (4 major and 0 minor) among 14 pregnancy losses with histopathological exam (16%; 14/79)
Restricted to pregnancies with information on the presence or absence of a birth defect; 16 birth defects (7 major and 9 minor) among 421 live born and 2 defects (2 major and 0 minor) among 10 pregnancy losses with histopathological exam (17%; 10/58)
Adjusted for maternal age (continuous), BMI categories (≤25; 26–30, >31, missing), maternal hypertension (yes/no), use of >1 medication (yes/no), centre 8 (yes/no)
Contains two minor birth defects (1 patent or persistent foramen ovale; 1 interventricular septal hypertrophy)
Contains two minor birth defects (1 patent or persistent foramen ovale; 1 patent ductus arteriosus)